A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
Public ClinicalTrials.gov record NCT06807463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
Study identification
- NCT ID
- NCT06807463
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- TEV-53408 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2025
- Primary completion
- Sep 14, 2026
- Completion
- Sep 13, 2027
- Last update posted
- Apr 7, 2026
2025 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12138 | Murrieta | California | 92563 | — |
| Teva Investigational Site 12131 | Colorado Springs | Colorado | 80907 | — |
| Teva Investigational Site 12134 | Inverness | Florida | 34452 | — |
| Teva Investigational Site 12126 | Miami Lakes | Florida | 33016 | — |
| Teva Investigational Site 12135 | New Port Richey | Florida | 34653 | — |
| Teva Investigational Site 12130 | Atlanta | Georgia | 30328 | — |
| Teva Investigational Site 12133 | Marrero | Louisiana | 70072 | — |
| Teva Investigational Site 12132 | Clinton Township | Michigan | 48038 | — |
| Teva Investigational Site 12121 | Wyoming | Michigan | 49519 | — |
| Teva Investigational Site 12129 | Rochester | Minnesota | 55905 | — |
| Teva Investigational Site 12128 | New York | New York | 10032 | — |
| Teva Investigational Site 12125 | Greenville | North Carolina | 27834 | — |
| Teva Investigational Site 12127 | Winston-Salem | North Carolina | 27103 | — |
| Teva Investigational Site 12137 | Waco | Texas | 76712 | — |
| Teva Investigational Site 12122 | Ogden | Utah | 84405 | — |
| Teva Investigational Site 12123 | Lynchburg | Virginia | 24502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06807463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06807463 live on ClinicalTrials.gov.